FDA rejects Abeona’s epidermolysis bullosa cell therapy, asks for CMC data
Yesterday the agency denied approval for Abeona Therapeutics’ investigational gene-corrected cell therapy prademagene zamikeracel (pz-cel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare disease that causes painful blistering and erosion of the skin.